Paul Cacchillo, MD
Ophthalmology · Indianapolis, INNPI 1902848765
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,097 of the $8,166 with a category attached, or 74.7%. 17 manufacturers reported payments, led by Glaukos Corporation at 30.9% of the total. Reporting peaked in 2023 at $2,449 and has fallen 90.5% since, to $233 in 2025.
Across 198 payments — averaging $41.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$3K
- Lensar, Inc.$2K
- AbbVie$2K
- Alcon$511
- Bausch & Lomb, A Division Of Bausch Health US, LLC$308
- Novartis$289
- plus $850 from 11 others
What the payments were for
- Speaking & faculty fees$2,02425%
- Food & beverage$6,09775%
- Gifts$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 8 | $2,527 |
| Lensar, Inc. | 22 | $2,014 |
| AbbVie(2 entities) | 79 | $1,666 |
| Alcon | 23 | $511 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $308 |
| Novartis | 19 | $289 |
| Rxsight Inc | 10 | $229 |
| Johnson & Johnson Surgical Vision, Inc. | 6 | $179 |
| Bausch & Lomb Americas Inc. | 6 | $125 |
| Biotissue Holdings Inc. | 5 | $59 |
| Thea Pharma Inc. | 3 | $57 |
| Lombart Brothers, Inc. | 1 | $55 |
| Sight Sciences, Inc. | 2 | $34 |
| Carl Zeiss Meditec USA, Inc. | 2 | $34 |
| Dompe US, Inc. | 1 | $32 |
| Kala Pharmaceuticals, Inc. | 2 | $26 |
| Shire North American Group Inc | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LENSAR LASER SYSTEM$1,746
- iStent inject Trabecular Micro-Bypass System Model G2-M-IS$1,500
- iStent infinite Trabecular Micro-Bypass System Model iS3$345
- iStent Trabecular Micro-Bypass System Model iS3$332
- RADIUS$302
- DURYSTA$239
- iS3-iStent infiniteTrabecular Micro-Bypass System Model iS3$173
- LUMIGAN$150
- BESIVANCE$125
- Tecnis 1-piece IOL$124
- Tecnis Symfony IOL$124
How this compares
$8,166 in reported general payments places this provider in the 85th percentile of 266 ophthalmology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 288 | $144,074 |
| RestasisCyclosporine | 40 | $34,277 |
| CombiganBrimonidine Tartrate/Timolol | 74 | $30,971 |
| Alphagan PBrimonidine Tartrate | 34 | $21,543 |
| Prednisolone Acetate | 188 | $9,383 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 12 | $9,208 |
| RocklatanNetarsudil Mesylat/Latanoprost | 15 | $5,183 |
| Ketorolac Tromethamine | 162 | $4,177 |
| Latanoprost | 410 | $4,020 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 31 | $3,648 |
| Travoprost | 30 | $3,400 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 134 | $2,742 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 11 | $2,504 |
| Timolol Maleate | 126 | $2,318 |
| MoxifloxacinMoxifloxacin Hcl | 58 | $1,927 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $1,666 | $230,865436 claims |
| AlconSimbrinza | $511 | $9,20812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 266 ophthalmology providers in Indiana.
Other ophthalmology in Indianapolis
- Kevin WaltzIndianapolis$199K
- Janet HummerIndianapolis$96K
- Francis PriceIndianapolis$67K
- Michael OrrIndianapolis$26K
- Matthew FengIndianapolis$22K
- John LindIndianapolis$20K
- Shaohui LiuIndianapolis$19K
- John LatonaIndianapolis$18K
- William WhitsonIndianapolis$15K
- Thierry WilbrandtIndianapolis$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.